# EDGAR Filing Document

**Accession Number:** 0001235912
**File Stem:** 0001104659-23-032814
**Filing Date:** 2023-3
**Character Count:** 4857
**Document Hash:** b5b99085bae4a9cbbf7b202d13995dac
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-032814.hdr.sgml**: 20230315

**ACCESSION NUMBER**: 0001104659-23-032814

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230313

**ITEM INFORMATION**: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

**FILED AS OF DATE**: 20230315

**DATE AS OF CHANGE**: 20230315

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CVRx, Inc.
- **CENTRAL INDEX KEY:** 0001235912
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40545
- **FILM NUMBER:** 23735663

**BUSINESS ADDRESS:**
- **STREET 1:** 9201 WEST BROADWAY AVENUE
- **STREET 2:** SUITE 650
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55445
- **BUSINESS PHONE:** 7634162850

**MAIL ADDRESS:**
- **STREET 1:** 9201 WEST BROADWAY AVENUE
- **STREET 2:** SUITE 650
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55445

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CVRX INC
- **DATE OF NAME CHANGE:** 20030527

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **March 13, 2023**

**CVRx, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40545** | **41-1983744** |
| (State or other jurisdiction of<br> incorporation) | (Commission<br> File Number) | (I.R.S. Employer<br> Identification No.) |

---

**9201 West Broadway Avenue** **, Suite 650** 

**Minneapolis** **, MN 55445**

(Address of principal executive offices) (Zip Code)

**(763) 416-2840**

(Registrant's telephone number, including area code)

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<u>see</u> General Instruction A.2. below):

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange<br> on which registered |
| **Common stock, par value $0.01 per share** | **CVRX** | **The Nasdaq Global Select Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.**

Pursuant to a borrowing notice CVRx, Inc. (the "Company") provided to Innovatus Life Sciences Fund I, LP ("Innovatus") on Friday, March 10, 2023, CVRx borrowed the $7.5 million remaining under the first tranche of its term loan facility with Innovatus, with $4.0 received on March 13, 2023 and $3.5 million received on March 15, 2023. The Company exercised its option to draw the remaining portion of the first tranche in light of the uncertainty in the banking industry. Following this draw, the Company will have $15.0 million in outstanding term loans under the Innovatus facility. The term loan facility continues to provide for two additional tranches of loans totaling up to an additional $35.0 million, based on the timing and other conditions set forth in the loan agreement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **CVRx, Inc.** | **CVRx, Inc.** |
| Date: March 15, 2023 | By: | /s/ Jared Oasheim |
|  |  | Name: Jared Oasheim |
|  |  | Its: Chief Financial Officer |

---